Journal of the American Chemical Society · 2003 · 83 citations · 16 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationComputational Drug DiscoveryDe Novo Drug DesignLigand BindingPeptide Drug DiscoveryProtein DesignProtein-ligand DockingComputational Peptide DesignDeterministic Global OptimizationExperimental ValidationPairwise Interaction PotentialsPeptide Library DesignPeptide Medicinal ChemistryPeptide Sequence OptimizationPeptide Structure - Activity Relationships
A novel structure-activity-based combinatorial computational optimization methodology for the design of peptides that are candidates to become therapeutics is presented. This methodology has been successfully applied in the design of a 7-fold more active analogue, among other active analogues, in the case of the complement inhibitor compstatin. The main steps of the approach involve the availability of NMR-derived structural templates, combinatorial selection of sequences based on optimization of parametrized pairwise residue interaction potentials, prediction of fold stabilities using deterministic global optimization, and experimental validation with immunological activity measurements. This work is direct evidence that an integrated experimental and theoretical approach can make the engineering of compounds with enhanced immunological properties possible.
16
De Novo Protein Design: Fully Automated Sequence Selection
Bassil I. Dahiyat, Stephen L. Mayo · Science · 1997 · 1.2K citations
The dead-end elimination theorem and its use in protein side-chain positioning
Johan Desmet, Marc De Maeyer, Bart Hazes et al. · Nature · 1992 · 696 citations